{"url_path":"/sec/nbp/10-k/2026/item-6","section_key":"item-6","section_title":"Item 6 DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES","topic":"sec","document":{"doc_type":"20-F/A","doc_date":"2026-06-16","source_url":"https://www.sec.gov/Archives/edgar/data/1778016/0001778016-26-000006-index.html","accession_number":"0001778016-26-000006","cik":"0001778016","ticker":"NBP","issuer_name":"NovaBridge Biosciences","edgar_url":"https://www.sec.gov/Archives/edgar/data/1778016/0001778016-26-000006-index.html","primary_entity_key":"0001778016","primary_entity_name":"NovaBridge Biosciences"},"word_count":1150,"has_tables":true,"body_markdown":"## ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES\n\nE. Share Ownership\n\nThe following table sets forth information with respect to the beneficial ownership of our ordinary shares as of March 24, 2026 by:\n\n•\neach of our directors and executive officers; and\n\n•\neach person known to us to beneficially own 5% or more of our total outstanding shares.\n\nPercentage of beneficial ownership is based on 265,991,561 total outstanding ordinary shares as of March 24, 2026.\n\nBeneficial ownership is determined in accordance with the rules and regulations of the SEC. In computing the number of shares beneficially owned by a person and the percentage ownership of that person, we have included shares that the person has the right to acquire within 60 days, including through the exercise of any option, warrant or other right or the conversion of any other security. These shares, however, are not included in the computation of the percentage ownership of any other person. The beneficial owners shown in the table below may hold ordinary shares and/or ADSs. The values in the table are presented on an ordinary share basis for uniformity.\n\n1\n\n \n\n \n\nOrdinary Shares Beneficially Owned\n\n \n\n \n\nNumber(1)\n\n \n\n \n\n%\n\n \n\nDirectors and Executive Officers:**\n\n \n\n \n\n \n\n \n\n \n\n \n\nWei Fu (2)\n\n \n\n \n\n30,499,709\n\n \n\n \n\n \n\n11.5\n\n \n\nEmmett T. Cunningham, Jr. M.D., Ph.D, MMPH\n\n \n\n \n\n—\n\n \n\n \n\n \n\n—\n\n \n\nChun Kwok Alan Au\n\n \n\n \n\n262,414\n\n \n\n \n\n*\n\n \n\nConor Chia-hung Yang\n\n \n\n \n\n262,414\n\n \n\n \n\n*\n\n \n\nRobert Lenz, M.D., Ph.D.\n\n \n\n \n\n—\n\n \n\n \n\n \n\n—\n\n \n\nXin Liu\n\n \n\n \n\n—\n\n \n\n \n\n \n\n—\n\n \n\nIan Ying Woo\n\n \n\n \n\n—\n\n \n\n \n\n \n\n—\n\n \n\nXi-Yong (Sean) Fu\n\n \n\n \n\n775,698\n\n \n\n \n\n*\n\n \n\nSean Wuxiong Cao, Ph. D.\n\n \n\n \n\n101,023\n\n \n\n \n\n*\n\n \n\nPhillip Dennis, M.D., Ph.D.\n\n \n\n \n\n1,068,824\n\n \n\n \n\n*\n\n \n\nMing (Kyler) Lei\n\n \n\n \n\n—\n\n \n\n \n\n \n\n—\n\n \n\nLiwei (Lorraine) Lin\n\n \n\n \n\n—\n\n \n\n \n\n \n\n—\n\n \n\nCong (Claire) Xu\n\n \n\n \n\n741,308\n\n \n\n \n\n*\n\n \n\nAll Directors and Executive Officers as a Group\n\n \n\n \n\n33,711,390\n\n \n\n \n\n \n\n12.7\n\n \n\nOther Principal Shareholders:\n\n \n\n \n\n \n\n \n\n \n\n \n\nEverest Medicines Limited (3)\n\n \n\n \n\n42,524,716\n\n \n\n \n\n \n\n16.0\n\n \n\nC-Bridge entities (4)\n\n \n\n \n\n30,499,709\n\n \n\n \n\n \n\n11.5\n\n \n\nT INVESTMENT LIMITED (5)\n\n \n\n \n\n18,795,651\n\n \n\n \n\n \n\n7.1\n\n \n\nHillhouse entities (5)\n\n \n\n \n\n13,755,306\n\n \n\n \n\n \n\n5.2\n\n \n\n \n\n___________\n\n* Less than 1% of our total ordinary shares on an as-converted basis outstanding as of March 24, 2026.\n\n** Except as otherwise indicated below, the business address of our directors and executive officers is 2440 Research Blvd, Suite 400, Rockville, MD 20850, the United States.\n\n(1)\nIncludes the amount of ordinary shares underlying options exercisable, and RSUs scheduled to vest, within 60 days of March 24, 2026. For details regarding these grants, see “—B. Compensation” above.\n\n(2)\nRepresents (i) 5,123,549 ADSs (representing 11,784,164 ordinary shares) directly held by CBC Investment I-Mab Limited, a British Virgin Islands limited liability company, (ii) 1,583,284 ADSs (representing 3,641,554 ordinary shares) directly held by IBC Investment Seven Limited, a Hong Kong limited liability company, (iii) 2,423,721 ADSs (representing 5,574,560 ordinary shares) directly held by CBC SPVII LIMITED, a Hong Kong limited liability company, (iv) 1,030,237 ADSs (representing 2,369,546 ordinary shares) directly held by C-Bridge II Investment Ten Limited, a British Virgin Islands limited liability company, and (v) 3,099,950 ADSs (representing 7,129,885 ordinary shares) directly held by Nova Aqua Limited, a British Virgin Islands limited liability company that is held through a trust established by Mr. Wei Fu (as the settlor) for the benefit of Mr. Wei Fu and his family. IBC Investment Seven Limited, CBC SPVII LIMITED, CBC Investment I-Mab Limited and C-Bridge II Investment Ten Limited are collectively referred to as the C-Bridge entities. CBC Investment I-Mab Limited and C-Bridge II Investment Ten Limited are controlled by C-Bridge Healthcare Fund II, L.P., whose general partner is C-Bridge Healthcare Fund GP II, L.P., and its general partner is C-Bridge Capital GP, Ltd. CBC SPVII Limited and IBC Investment Seven Limited are controlled by I-Bridge Healthcare Fund, L.P., whose general partner is I-Bridge Healthcare GP, L.P., and its general partner is I-Bridge Capital GP, Ltd., which is indirectly controlled by C-Bridge Capital GP, Ltd. Mr. Wei Fu is the sole director of C-Bridge Capital GP, Ltd. Information relating to the C-Bridge entities and regarding beneficial ownership is based on the information contained in the Schedule 13D/A filed by the C-Bridge entities on February 3, 2026. The business address of these entities is 88 Market Street, #46-04/05 Capitaspring, Singapore (048948).\n\n(3)\nRepresents 42,524,716 ordinary shares directly held by Everest Medicines Limited, a Cayman Islands limited liability company. Information relating to Everest Medicines Limited and regarding beneficial ownership is based on the information contained in the Schedule 13D filed by Everest Medicines Limited on August 5, 2025. Everest Medicines Limited is a public company listed on the HKEX and controlled by funds which are under common\n\n2\n\n \n\n \n\n \n\ncontrol of the C-Bridge entities (as defined below), which, in turn, are controlled by Mr. Wei Fu. The business address of Everest Medicines Limited is 36 Robinson Road, #20-01 City House, Singapore 068877.\n\n(4)\nRepresents 8,172,022 ADSs (representing 18,795,651 ordinary shares) directly held by T INVESTMENT LIMITED. Information regarding beneficial ownership is reported as of November 23, 2023, derived from the information contained in the Schedule 13D filed by T INVESTMENT LIMITED on December 1, 2023, assuming the shares reported thereunder refer to the ADSs. Please see the Schedule 13D filed by T INVESTMENT LIMITED with SEC on December 1, 2023 for information relating to T INVESTMENT LIMITED. The business address of T Investment Limited is Flat B, 4th Floor, Haven Commercial Building 6-8, Tsing Fung Street, Hong Kong.\n\n(5)\nRepresents 5,980,568 ADSs (representing 13,755,306 ordinary shares) held by funds managed by HHLR Advisors, Ltd., or HHLR, an exempted Cayman Islands company. HHLR acts as the sole investment manager of YHG Investment, L.P., or YHG, and the sole management company of HHLR Fund, L.P., or HHLR Fund. HHLR is hereby deemed to be the beneficial owner of, and to control the voting and investment power of, the voting ordinary shares held by YHG and HHLR Fund. HIM acts as the sole management company of Hillhouse Fund IV, L.P., or Fund IV. Fund IV owns HH IMB Holdings Limited, or HH IMB. HIM is hereby deemed to be the beneficial owner of, and to control the voting and investment power of, the voting ordinary shares held by HH IMB. HH IMB, YHG and HHLR Fund are collectively referred to as the Hillhouse entities. Information regarding beneficial ownership is reported as of December 31, 2025, based on the information contained in the Form 13F filed by HHLR on February 17, 2026. The business address of HHLR is Office #122, Windward 3 Building, Regatta Office Park, West Bay Road, Grand Cayman, Cayman Islands, E9 KY1-9006.\n\nTo our knowledge, as of March 24, 2026, 258,164,444 of our ordinary shares were held by three record holders in the United States, representing approximately 97% of our total outstanding shares, substantially all of which were held by Citibank, N.A. (“Citibank”), the depositary of our ADS program. The number of beneficial owners of our ADSs in the United States is likely to be much larger than the number of record holders of our ordinary shares in the United States. We are not aware of any arrangement that may, at a subsequent date, result in a change of control of our company."}